Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CaptAin - Effect of Capivasertib on ctDNA in ER Positive Breast Cancer

NCT06613516 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.

NCT NCT06613516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06613516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CaptAin - Effect of Capivasertib on ctDNA in ER Positive Breast Cancer
Lead sponsor
Imperial College London
Phase
Phase 2
Overall status
Withdrawn
Start date
February 1, 2025
Completion date
September 16, 2025
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, oestrogen receptor positive breast cancer